The FDA Is Seeking to Revoke Approval of the Vasculitis Drug Tavneos Amid Allegations of Data Manipulation
The United States Food and Drug Administration (FDA) has formally moved to withdraw its approval for Tavneos (avacopan), a high-priced medication prescribed for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a rare and potentially fatal autoimmune disorder. This regulatory action follows a series of revelations suggesting that the pivotal clinical trial data used to secure the drug’s 2021 market authorization was fundamentally compromised by unauthorized data manipulation. The case has sent shockwaves through the pharmaceutical industry, prompting a rare retraction from the New England Journal of Medicine and a cascade of market withdrawals in the United Kingdom and the European Union.
A Timeline of Regulatory Controversy
The saga of Tavneos began in May 2021, when the FDA released a critical briefing document ahead of a meeting of its Cardiovascular and Renal Drugs Advisory Committee. The agency expressed significant reservations regarding the efficacy of avacopan, noting that the trial design conducted by the California-based biotechnology firm ChemoCentryx was suboptimal. Despite internal FDA skepticism and split votes among independent experts—some of whom questioned whether the drug provided a meaningful benefit over existing standard-of-care therapies—the agency granted approval on October 7, 2021.
The approval was predicated on the promise that Tavneos would allow patients to reduce their reliance on long-term corticosteroid use, which is known to cause severe side effects, including weight gain, mood instability, and sleep disturbances. However, the integrity of the clinical trial became the subject of intense scrutiny following an investor lawsuit against ChemoCentryx. During legal discovery, evidence emerged that the company had engaged in an unauthorized "readjudication" of trial data. According to the FDA, employees unblinded the trial—viewing which patients received the drug versus a placebo—and subsequently selected specific patient outcomes for reassessment to artificially inflate the drug’s apparent efficacy.
In April 2026, the FDA issued a formal proposal to withdraw the drug from the U.S. market, citing reports of serious liver injuries and a lack of "substantial evidence" that the drug functions as claimed. Following this, the New England Journal of Medicine retracted the 2021 paper detailing the trial results, and regulatory bodies in the UK and the EU moved to pull the product from their respective markets.
The Financial Stakes and Industry Context
The commercial trajectory of Tavneos has been marked by staggering growth and significant consolidation. One year after the drug’s approval, the pharmaceutical giant Amgen acquired ChemoCentryx in a deal valued at approximately $4 billion. At a list price of $220,000 per year, the drug has become a major revenue driver, generating nearly half a billion dollars in sales during the 2025 fiscal year.
The acquisition highlights a broader trend in the pharmaceutical sector, where large, established companies increasingly rely on "nimble" biotech startups to navigate the early, high-risk phases of drug development. However, industry analysts, such as David Ridley of Duke University, note that this model creates unique incentives. When a small company’s entire valuation is tied to the success of a single experimental drug, the pressure to deliver favorable results can be immense, leading some firms to compromise on clinical rigor.
Amgen’s Defense and the Patient Perspective
Amgen has mounted a vigorous defense of the drug, submitting a 104-page document to the FDA in July 2026 arguing that the "totality of the evidence" supports the continued availability of Tavneos. The company maintains that while the internal re-adjudication process conducted by ChemoCentryx did not align with their own corporate standards, it did not alter the underlying clinical data. Amgen asserts that the reassessment was performed to correct minor errors and that the company was not legally obligated to disclose the internal review to the FDA at the time.
For patients, the potential removal of the drug presents a difficult dilemma. Patients like Chloe Cusano, who was diagnosed with AAV in late 2025, credit the medication with allowing them to taper off high-dose steroids, which had significantly impaired their quality of life. Proponents of the drug, including some academic researchers, argue that real-world evidence suggests the drug is effective when used under close medical supervision. Eric Roberts, an epidemiologist at the University of California, San Francisco, who co-authored an independent registry study, stated that the drug appears efficacious and that the risks of liver injury, when monitored, are manageable compared to the known hazards of long-term steroid therapy.
Broader Implications for Regulatory Integrity
The Tavneos case serves as a diagnostic test for the FDA’s regulatory oversight mechanisms. Reshma Ramachandran, co-director of the Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, argues that the situation is emblematic of the agency’s struggle to manage drugs with uncertain efficacy. "Absent more rigorous studies," she notes, "we are living in a state of perpetual uncertainty regarding whether these drugs actually work."
The FDA’s current stance is that the integrity of the approval process is paramount. By allowing a drug to remain on the market after evidence of data manipulation, the agency fears it would set a dangerous precedent, signaling to other manufacturers that deceptive practices might be tolerated if the drug is eventually deemed "useful" by a subset of patients.
Furthermore, the failure of the company to meet deadlines for post-marketing studies—a common requirement for drugs approved under accelerated pathways—has drawn criticism. Joshua Skydel, a clinical fellow at Yale New Haven Hospital, emphasizes that the reliance on industry-led, non-peer-reviewed data to justify a drug’s continued market presence is problematic. "This episode highlights the vulnerability of the drug approval system when it relies on an assumption of trust that may not be warranted," Skydel said.
Looking Ahead: The Path to Withdrawal
The legal process for withdrawing a drug is intentionally methodical. The FDA must provide notice and offer the manufacturer an opportunity for a public hearing to contest the findings. Should Amgen choose to challenge the withdrawal in court, the case could lead to a protracted legal battle that would leave physicians and patients in a state of suspended animation.
As of late October 2026, a court hearing regarding a proposed $69 million settlement for the initial securities fraud lawsuit is pending. Meanwhile, the FDA remains under pressure to uphold its standards. Acting director of the FDA’s Center for Drug Evaluation and Research (CDER), Tracy Beth Høeg, has described the case with stark candor, noting that the drug was authorized based on a foundation of manipulated data.
Ultimately, the Tavneos saga has forced a reckoning regarding the safeguards intended to protect the public. The reliance on small, potentially desperate startups for breakthrough medicine, coupled with a regulatory environment that often prioritizes speed over comprehensive, unassailable data, has created a system where patient outcomes are potentially being influenced by corporate malfeasance. Whether the FDA successfully withdraws Tavneos or finds a middle ground through mandated additional studies remains to be seen, but the event has already permanently altered the landscape of rheumatological research and the public’s trust in the pharmaceutical pipeline.
The case will likely serve as a foundational case study for years to come, illustrating the critical necessity of transparency, the perils of unverified data, and the enduring tension between the urgent need for new therapies and the absolute requirement for scientific truth.
